Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Did anyone actually go?
Good to see directors participating in the placing.
I'm with MisterH on this, why the hell did they waste vast sums of money on an utterly pointless telephone directory. BOD utterly out of touch with reality and no friend of the PI
They had one this time last year for 130p investors then are losers now.
You can buy lower than placing price now!
£3k added.
Not worrying. Suprised they did not go for more though so placing clouds can be removed for a couple of years.
Hopefully enough though - diff to get balance between min dilution and stability
I'm with you Agricore and very happy with my investment here. Yes the placing came at a shock yesterday and I'm disappointed we weren't invited to participate but I expect we'll find out soon why that was.
They had £2.7mil cash at EOY and they've invested in Qbot and Vortex since then. They should still have had plenty of cash so I think they have a plan for this £1.5mil that they needed it asap.
You only need to go back a short way to see how the BOD are generating shareholder value. Qbot generated 6p/share last week on the upround for example. Did you miss that?! Generally there's been a severe derating of Biotech which has hit PDS for example. However this has now bottomed and the outlook from PDS phase 2 trials are strong. Biotech is fairly recession proof too!
You can moan about "brazenness" (sic) and "bloated salaries" but I'm pleased with how the BOD are leading the business and the commercial decisions they are making. Just sell up if you don't share that belief.
What I'm disappointed with is that this discounted offering was made to ii's - and private investors were excluded from the raise. I have written to the company to express my disappointment. Assuming you are a PI like me, I suggest you do the same.
Disappointed to see a discounted placing. BOD needs to do something fairly quick to show shareholder value.
Well, there we have it, another placing at mate's rates. A jaw dropping 54% discount to estimated fair value of £1.47 per share. They then have the brazenness to boast about the successful £7.3M raised during the year at £1.30. Hardly a sound investment for those poor mugs. Starting to look like a 'lifestyle' company run purely for the benefit of directors. I am not aware of any successful exits and the supposed wonder company PDSB is starting to look like a basket case if the SP is anything to go by.
Did anyone else get the telephone directory sized annual report? Obviously money to burn. At least we got to learn about the bloated salaries and share based payments that the directors enjoy.
Been following EMV for a while on there, never thought to follow NSCI though!
Great to see PointGrab are doing well, that was quite an interesting read.
And SageTech getting ISO accreditation, it really is about time they were getting rolled out in more hospitals!
The W H Ireland research note increasing valuation of NSCI to 190p is reassuring too.
Worth following them on LinkedIn. You get a lot more info via this channel on the portfolio companies.
Great interview. Didn’t realise Q-bot was already operating outside the UK.
Valuable patent as well!
Thanks for the response tqhussain, appreciate it. Definitely interesting reading
I originally invested in NSCI because of Glycotest which, if successful will be real money maker. In the annual report they have given a lot more detail about it's current status.
Vortex bio also has great potential, just look at AGL!
Wilco, Below are a couple of examples that I have seen which give you a feel for the scope.
https://www.pbctoday.co.uk/news/planning-construction-news/social-housing-disruptors-framework/105366/
https://www.housing-technology.com/q-bot-underfloor-robots-at-plus-dane/
From what I have seen, at the beginning Q-bot was mainly doing private one off household type jobs. Now they involved in framework agreements, housing authorities etc.
Anyone the possible size of the addressable market for Q-Bot?
Not massively well versed and primarily in NSCI for the PDSB stake but sounds quite an exciting business
>> This round, which comprised conversion of £762,000 of loan notes (of which £500,000 was provided by NetScientific as announced on 21 December 2021) and £900,000 of new equity, results in the direct equity holding in Q-Bot by NetScientific increasing from 18.3% to 20.6%, in addition to EMVC's Capital Under Advisory representing 16.7%. NetScientific's 20.6% Q-Bot direct stake is valued at £2.77m based on this funding round- a gain of approximately £1.45m in less than one year.
That (paper) gain equates to around a 6p gain on the current share price. Not bad!
https://www.biospace.com/article/circulating-tumor-cells-market-size-to-surpass-us-20-3-bn-by-2030/
"Advancements in technologies such as immunofluorescence, NGS, FISH, and qPCR are anticipated to drive the clinical utility of these cells, and thus accelerating revenue growth for CTC analyses. Several companies are investing in the development of products that help in CTC analysis and downstream assays. For instance, Vortex Biosciences offers various CTC analysis products, including immunofluorescence, cytopathology, cytogenetics (FISH), cell culture, and genomics."
Fantastic RNS